Should I Buy QNTM? QNTM 2026 Analysis

Should You Buy Quantum Biopharma Ltd (QNTM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.200

1 Day change

7.14%

52 Week Range

38.250

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now. Despite being extremely oversold (RSI ~12.8) and capable of a short-term bounce, QNTM is in a clear bearish trend (SMA200 > SMA20 > SMA5, negative MACD) and is facing heavy lawsuit-driven negative sentiment. With no proprietary buy signals today and weak/limited fundamental momentum (no revenue, ongoing losses), an impatient buyer is better off staying out rather than trying to catch a falling knife.

Technical Analysis

Trend/Structure: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), signaling sustained downside momentum. Momentum: MACD histogram is -0.145 (below zero) and negatively contracting, consistent with bearish conditions (selling pressure still present, though contraction can precede a pause). Overbought/Oversold: RSI_6 at 12.816 indicates extremely oversold conditions, which increases the odds of a reflex bounce, but does not by itself confirm a trend reversal. Key levels: Pivot 5.919 is overhead (near-term resistance zone). Support levels: S1 4.903 (current price 4.85 is slightly below/near this area) and S2 4.275 (next notable downside level). Upside resistances: R1 6.935, R2 7.563. Pattern-based forward look: Similar-pattern analysis suggests a 60% chance of -0.72% next day, +1.35% next week, +4.49% next month—i.e., near-term chop/down with potential modest recovery later.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

can fuel a short-term technical rebound.

Neutral/Negative Catalysts

create strong negative sentiment and headline risk.

Financial Performance

Latest reported quarter: 2025/Q3.

Revenue: 0 (0.00% YoY), indicating no meaningful top-line traction in the snapshot.
Net income: -5,319,029 (improved 32.47% YoY), a narrower loss year-over-year.
EPS: -1.4 (down 67.96% YoY), showing per-share performance deteriorated despite the net loss improvement (possible share count/other effects). Overall: Still loss-making with no revenue showing in the snapshot; fundamentals do not currently provide a strong base for an impatient long entry.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target changes were provided in the data. As a result, there is no visible Wall Street consensus to offset the bearish technicals and lawsuit-driven negative headlines. Pros (if any) are not evidenced by ratings/targets here; cons are currently dominated by legal/headline risk and weak fundamentals.

Analyst Rating

Wall Street analysts forecast QNTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNTM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 3.920

Low

Averages

High